Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Idera Pharmaceuticals (IDRA)

Idera Pharmaceuticals (IDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Idera Pharmaceuticals 505 EAGLEVIEW BLVD. SUITE 212 EXTON PA 19341 USA

www.iderapharma.com P: 484-348-1600

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances.

Key Statistics

Overview:

Market Capitalization, $K 26,501
Enterprise Value, $K -6,049
Shares Outstanding, K 62,355
Float, K 53,126
% Float 85.20%
Short Volume Ratio 0.24
% of Insider Shareholders 14.80%
% of Institutional Shareholders 12.18%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ 98,090 K
Last Quarter Sales, $ 50 K
Last Quarter Net Income, $ -3,100 K

Growth:

1-Year Return -35.03%
3-Year Return -77.27%
5-Year Return -97.16%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 75.83%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.06 on 11/14/22
Next Earnings Date 03/30/23
Earnings Per Share ttm -0.32
EPS Growth vs. Prev Qtr 40.00%
EPS Growth vs. Prev Year 45.45%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-17 on 01/18/23

IDRA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -68.74%
Return-on-Assets % -34.27%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales 459.69
Price/Cash Flow 0.23
Price/Book 1.09
Book Value/Share 0.94
Interest Coverage 9,810.00
60-Month Beta 1.25
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar